Stephen H. Shoemaker - 29 Jul 2025 Form 4 Insider Report for 180 Life Sciences Corp. (ATNF)

Role: Director
Signature: /s/ Stephen H. Shoemaker
Issuer symbol: ATNF
Transactions as of: 29 Jul 2025
Net transactions value: $0
Form type: 4
Filing time: 07 Aug 2025, 16:15:18 UTC
Previous filing: 14 Jul 2025
Next filing: 11 Aug 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Shoemaker Stephen H	Director	3000 EL CAMINO REAL, BLDG. 4,, SUITE 200, PALO ALTO	/s/ Stephen H. Shoemaker	07 Aug 2025	0002048098

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ATNF	Common Stock						132,439	29 Jul 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATNF	Non-Qualified Stock Option (right to buy)	Award	$0	+919,761		$0.000000	919,761	29 Jul 2025	Common Stock	919,761	$2.92	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The options were granted under the 2025 Supplemental Option Plan of the Issuer. The options vested immediately, but were not exercisable until or unless the closing of the transactions contemplated by the July 29, 2025, Securities Purchase Agreement between the Issuer and the purchasers set forth therein occurred, which closing date was August 4, 2025. Separately, the options are not exercisable until stockholder approval of the 2025 Plan is received. If stockholder approval is not received prior to July 29, 2026, the options will be cancelled.
F2	Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a director of the Issuer.

Content

The options were granted under the 2025 Supplemental Option Plan of the Issuer. The options vested immediately, but were not exercisable until or unless the closing of the transactions contemplated by the July 29, 2025, Securities Purchase Agreement between the Issuer and the purchasers set forth therein occurred, which closing date was August 4, 2025. Separately, the options are not exercisable until stockholder approval of the 2025 Plan is received. If stockholder approval is not received prior to July 29, 2026, the options will be cancelled.

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a director of the Issuer.